FDA weighs new COVID antibody drug that could be 'holy grail' for immunocompromised: AZD7442 showed 77% efficacy, AstraZeneca said

FDA weighs new COVID antibody drug that could be 'holy grail' for immunocompromised: AZD7442 showed 77% efficacy, AstraZeneca said: https://ift.tt/3bBoI5e Read more... https://ift.tt/3BFmvjy